Table 2.
IC50 of total GAG, HS, and the mix of CS and KS for FGF2 and VEGF. IC50 were determined in μg/mL and defined as the concentration of tested cartilage GAG able to compete with heparin for 50% of the binding to HBP (FGF2 and VEGF), and used to calculate the % of binding affinity shown in Fig. 3
| IC50 (μg/ml) | CT | Femur | Tibial Plateau | Patella | OA |
|---|---|---|---|---|---|
| Total GAG | |||||
| FGF-2 | 11 ± 4 | 88 ± 23 | 75 ± 23 | 91 ± 1 | 84 ± 20 |
| VEGF | NoC | 113 ± 76 | 187 ± 125 | 106 ± 36 | 136 ± 78 |
| HS | |||||
| FGF-2 | 34 ± 14 | 74 ± 31 | 88 ± 8 | 110 ± 30 | 82 ± 25 |
| VEGF | 13 ± 2 | 39 ± 19 | 45 ± 3 | 21 ± 2 | 38 ± 12 |
| CS + KS | |||||
| FGF-2 | NoC | NoC | NoC | NoC | NoC |
| VEGF | NoC | NoC | NoC | NoC | NoC |
Values correspond to the mean ± SEM for the CT group (n = 7) compared to the different parts of OA cartilages: femur (F), tibial plateau (TP), and patella (P) and to all OA cartilage parts (OA, n = 11). Each GAG sample was analyzed in duplicate in three independent experiments. NoC no competition, HS heparan sulfate, KS keratan sulfate, CS chondroitin sulfate